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Abstract
Background: Sentinel lymph node (SLN) biopsy is a widely used diagnostic procedure in the
management of early breast cancer. When SLN is free of metastasis, complete axillary dissection
may be skipped for staging in clinically N0 patients, allowing a more conservative procedure.
Histological tumor features that could reliably predict SLN status have not yet been established.
Since the degree of tumor lymphangiogenesis and vascularization may theoretically be related to
the risk of lymph node metastasis, we sought to evaluate the relationship between lymph vessel
invasion (LVI), lymphatic microvascular density (LVD), microvascular density (MVD) and VEGF-A
expression, with SLN status and other known adverse clinical risk factors.
Methods: Protein expression of D2–40, CD34, and VEGF-A was assessed by
immunohistochemistry on paraffin-embedded sections of primary breast cancer specimens from 92
patients submitted to SLN investigation. The presence of LVI, the highest number of micro vessels
stained for D2–40 and CD34, and the protein expression of VEGF-A were compared to SLN
status, clinicopathological features and risk groups.
Results: LVI was detected in higher ratios by immunostaining with D2–40 (p < 0.0001), what
would have changed the risk category from low to intermediate in four cases (4.3%). There was no
association between LVI and other angiogenic parameters determined by immunohistochemistry
with SLN macrometastases, clinical features or risk categories.
Conclusion: Assessment of LVI in breast carcinoma may be significantly increased by
immunostaining with D2–40, but the clinical relevance of altering the risk category using this
parameter may not be advocated according to our results, neither can the use of LVI and LVD as
predictors of SLN macrometastasis in early breast cancer.
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Breast cancer is the most frequent neoplasm in women in
several countries, including Brazil. In the last decades,
detection of disease in earlier clinical stages has improved
prognosis, however five-year disease-free survival of breast
cancer presenting with T1 to 3, N0–1, and M0 staging
remains at about 72% [1]. For this reason, continuing
efforts to establish reliable prognostic markers are made.
Malignant neoplasms are angiogenesis-dependent [2].
The prognostic value of the tumor microvascular density
(MVD) in breast cancer has been examined in several
studies, with correlations with tumor recurrence, disease-
free or overall survival [3-14]. Some discrepancies detect-
able on the subject may be explained by differences in
patients' selection (age, menopausal status, tumor type,
tumor size, adjuvant treatment, follow-up interval,
number of patients included in each study), and in mate-
rial and methods used (antibody's specificity, methods
used to assess MVD). Considering meta-analysis results,
significant evidence for the prognostic value of MVD in
breast cancer was detected, however it was weak [15]. Vas-
cular invasion around the tumor has been also considered
an adverse risk factor in node-negative breast carcinoma
[16]. It has been recently shown that assessing lym-
phovascular invasion (LVI) is related with other features
of aggressiveness of breast cancer, as high proliferation
index and low hormonal receptor [17]. In spite of the
number of publications on the subject, the value of LVI
and other angiogenesis markers in early breast carcinoma
has not been sufficiently explored in part because the lack
of reliable antibodies. The use of D2–40 in tumor pathol-
ogy to detect lymphatic vessels is growing, but some con-
troversy is expected because the experience in its use is
quite recent. In the present study it was our purpose to
evaluate the feasibility of vascular invasion assessed by
hematoxilin-eosin (H&E) and by immunostaining with
D2–40, as well as LVD, MVD and VEGF-A expression in
early breast carcinoma, and its correlation to sentinel
lymph node (SLN) status and to other clinicopathological
parameters.
Methods
Consecutive female patients diagnosed with early breast
carcinoma and submitted to SLN examination were
selected from 2004 to 2006 at the Women's Hospital of
the State University of Campinas Medical School, Uni-
camp, São Paulo, Brazil. The present study was performed
with the approval of the Committee of Ethics in Research
of our institution, and was carried out in compliance with
the Helsinki Declaration. Ninety-two cases were morpho-
logically reanalyzed, both tumor and SLN. Medical
records were revised; patient's age, tumor size, axillary
lymph node involvement, risk group, pathological staging
of tumor and lymph nodes and clinical evaluation for
metastasis (pT pN cM) were determined as markers of
aggressiveness. Staging was based on the AJCC Cancer
Staging Manual, 6th Edition (2002) [18]. Histologic grade
was determined by the modified Nottingham classifica-
tion, proposed by Elston & Ellis [19]. Risk groups were
classified according to Goldhirsh et al (2005) [16], as fol-
lows:
Low risk
Node negative AND all of the following features: pT ≤ 2
cm, AND histological grade 1, AND absence of peritu-
moral vascular invasion, AND HER2/neu gene neither
overexpressed nor amplified, AND age ≥ 35 years.
Intermediate risk
IF node negative AND at least one of the following fea-
tures: pT ≥ 2 cm, OR histological grade 2–3, OR presence
of peritumoral vascular invasion, OR HER2/neu gene
overexpressed or amplified, OR age < 35 years. OR IF less
than four nodes are positive, AND HER2/neu gene neither
overexpressed nor amplified.
High risk
One to three nodes positive AND Her2/neu gene overex-
pressed or amplified, OR four or more nodes positive.
Sentinel Node (SLN)
SLNs were detected using a combination of radioactive
colloid and Patent blue V. Three hours before surgery, 0.2
ml radioactive tracer (dextran mCi 99 mTc-labelled) was
injected subdermally at the tumor site. Twenty to 30 min-
utes afterwards, lymphatic scintillography was performed
to localize SLNs. The skin overlying the node was marked
with permanent ink. During the surgery, a blue dye (2 ml,
50 mg/ml) was applied at the lesion site by a subdermal
injection. SLNs were then detected simultaneously by a
hand-held gamma ray detecting probe and visual control.
All surgically removed SLNs underwent intraoperative
cyto- (imprints) and histopathological examination.
Gross processing of the nodes consisted of serial section-
ing in 1–2 mm thick slices, which were fixed in 10% for-
malin and embedded in paraffin. They were then
microscopically evaluated in serial H&E stained sections
at intervals of 150 μm [20]. In negative cases, two slide
samples were additionally stained with an anti-pancytok-
eratin antibody (AE1/AE3, Dako, Carpenteria, CA, USA;
1:200). As the clinical value of isolated neoplastic cells
and the presence of micrometastasis (0.2 – 2 mm) is still
controversial for decision taking, in the present study SLN
were considered positive for statistical analysis only when
they contained tumor foci greater than 2 mm (macrome-
tastasis).Page 2 of 8
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Briefly, two levels of 4-μm thick sections were obtained,
placed on silanized slides, deparaffinized in xylene and
rehydrated. Endogenous peroxidase activity was
quenched with 3% hydrogen peroxide. Antigen retrieval
was performed by heating slides in citrate buffer (10 mM,
pH 6.0) at 95°C for 30 minutes. The primary monoclonal
antibodies used were mouse anti-human VEGF-A
(CloneVG1, Dako, diluted at 1:100), CD34-Class II
(Clone QBend-10, Dako, 1:50), D2–40 (Clone D2–40,
Dako, 1:50), estrogen receptor (Clone 1D5, Dako, 1:150),
progesterone receptor (Clone PGR636, Dako, 1:300), and
HER-2/neu (Clone PN2A, Dako, 1:450). The Max Polymer
Detection System (Novolink, Novocastra, Newcastle, UK)
was used to reveal antigen-antibody reaction. Staining was
achieved using 3,3-diamonobenzidine tetrahydrochlride
(Sigma, St. Louis, MO, USA) and counterstaining using
Mayer's hematoxilin. All reactions were performed using
appropriate positive and negative controls.
All scores are represented by the mean of the two levels
evaluated by immunohistochemistry. Immunostaining
for hormone receptors were scored as negative or positive
(0 and 2 vs 3 to 8, according to Harvey et al, 1999) [21].
Immunostaining for HER-2/neu was scored as negative,
1+ to 3+, according to previously described parameters
[22]. Cases scored as 2+ were additionally submitted to
chromogenic "in situ" hybridization (CISH, Zymed's
SpoT-LightR HER2CISH™, Invitrogen, San Francisco, CA,
USA), according to the manufacturer's instructions [23].
VEGF-A expression was scored based on extent or percent-
age of positive cells (0: negative; 1: <25%; 2: 26–50%; 3;
51–75%; 4: > 75%) and staining intensity (0: negative; 1:
weak; 2: moderate; 3: strong). The sum of both parameters
resulted in a final VEGF-A score, which was then grouped
into three categories: negative to weak (0–2), moderate
(3–5) and strong (6–7) immunostaining.
Microvessel density and vascular invasion assessment
Blood and lymphovascular microvessel density were
assessed independently by two observers, without knowl-
edge of the patients' clinicopathologic data. Immunos-
tained tumor sections were scanned at low magnification
(40×) and the three most densely vascular areas ("hot
spots") were photographed at magnification 200× (0.74
mm2 per field). Vessels stained by CD34 or D2–40 were
counted using an image analysis software (Imagelab®, ver-
sion 2.4, São Paulo, Brazil). Tumor lymphatic vessel inva-
sion was established when at least one neoplastic cell
cluster was clearly visible inside a D2–40 positive lymph
vessel according to Yamauchi et al, 2006 [24]. Tumor lym-
phatic invasion thus determined was compared with the
one independently reported in H&E stains.
Statistical analyses
Statistical analysis was performed using the SAS System
for Windows software (version 9.1.3). Associations were
assessed using 2 × 2 or 2 × n contingency table analysis.
The Fisher's exact test was used to examine relationship
between VEGF-A expression and risk groups, pathological
stage and SLN status, as well as clinicopathological fea-
tures (tumor size, menopausal status, histological type,
histological grade, pathological stage, estrogen and pro-
gesterone receptors, Her2/neu expression, vascular inva-
sion on HE and on D2–40 stained slides) and sentinel
node status. Multiple logistic regression analysis was used
to evaluate the effect of microvascular density and vascu-
lar invasion markers, after adjusting for other potential
confounders such as age and tumor size. Correlations
between CD34 and D2–40 expression levels, as well as
between these antibodies and VEGF-A expression groups
were calculated using the linear Spearman's coefficient.
Vascular invasion on H&E and D2–40 staining were ana-
lyzed using the McNemar test. The Kappa value was calcu-
lated to assess inter-observer variability concerning VEGF-
A expression. The interclass correlation coefficient was
determined to evaluate inter-observer variability concern-
ing the expression of CD34 and D2–40. The significance
level was set at p = 0.05 for all tests.
Results
Median age of patients was 55 y (range 32–77 y). Twenty-
three patients were pre-menopausal and 69 menopausal.
Stage of disease was I in 58 patients, II in 26 and III in 8.
Tumor size presented a median of 12 mm (range 2–50
mm). Eighty cases corresponded to the ductal type, 5 were
lobular and 7 of other types. Histological grade was I in 36
patients, II in 47 and III in 9.
SLN was positive in 31 patients (33.7%), more frequently
in pre-menopausal women (52.1% vs. 27.5%; p = 0.03).
Patients with positive SLN were significantly younger:
median 53 y (range 33–68 y) vs 57 y (range 32–77 y; p =
0.013). Six patients were included in the low risk group
(6.5%), 73 in the intermediate risk group (79.3%) and 13
in the high risk group (14.2%). Estrogen receptor status
was positive in 77 patients and negative in 14. Progester-
one receptor was positive in 76 patients and negative in
15. HER2/neu status was negative in 61 patients and pos-
itive (either 3+ by immunohistochemistry or amplified by
CISH) in 29. In one patient it was not possible to assess
ER and PR status; the same occurred in two patients
related to HER2/neu status. (Lymph-)vascular invasion
(LVI) was present in 6.5% (six patients) of the cases on
H&E slides and in 29.3% (27 patients) on D2–40 stained
sections. The difference between both methods of evalua-
tion was significant (McNemar test: p < 0.0001). When
both methods of evaluation of LVI were compared to each
other, an agreement ratio of 75% was found (Table 1).Page 3 of 8
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to SLN status, either grouping the number of positive SLN
in 0 vs ≥ 1 (Table 2), or 0 and up to 3 vs ≥ 4 (Table 3), no
significant correlation was found. When both methods of
evaluation of LVI were compared to the three risk groups
(Table 4), only evaluation by H&E showed significant cor-
relation to risk groups (p = 0.04).
When patients' data were analyzed according to the pres-
ence (n = 28) and absence (n = 64) of LVI by either
method, H&E or D2–40, no correlation was found accord-
ing to patients' age, tumor size, histological type or grade,
MVD counts (CD34), LVD (D2–40), VEGF-A, HER-2/neu
and hormonal receptor status, or to SLN status.
Immunostaining with D2–40 would have resulted in
upgrade of risk group classification of four cases (4.3%).
Multiple logistic regression revealed a relationship
between SLN status and tumor size (p = 0.0012) and age
(p = 0.013). There was no relationship between SLN status
and all other clinicopathological variables: stage of the
disease, hormonal receptor and HER2/neu status, vascular
invasion (assessed by H&E or D2–40), VEGF-A immunos-
taining, MVD, or LVD (Table 5), after adjusting for tumor
size and age. There was no correlation between risk
groups, LVD, MVD or VEGF-A expression. Spearman's
coefficient between CD34, D2–40 and VEGF-A was low,
reflecting lack of significant correlation. Her2/neu was not
correlated to VEGF-A, CD34 and D2–40. The interclass
correlation coefficient between two observers related to
CD34 and D2–40 were, respectively, 0.995 (CI95% =
0.989–0.997) and 0.87 (CI95% = 0.63–0.90). Kappa
value was 0.7154 (CI95% = 0.48–0.95).
Discussion
The presence of lymph node metastasis is one of the most
important prognostic factors in breast cancer [25]. Our
data showed that only younger age, pre-menopausal sta-
tus (both parameters reflecting approximately the same
biological phenomenon), and larger tumor size were
related to SLN status, which is consistent with the known
adverse influence of these parameters in defining risk
groups, particularly in early breast cancer [26]. The
present data support the value of performing immunos-
taining using the antibody D2–40 to significantly
improve evaluation of LVI. This finding is in keeping with
most studies which performed the comparison between
assessments of LVI by H&E and D2–40 stains [17,24,27-
30]. However, as neither method significantly improved
predictability of SLN status in the current study, it is yet
not possible to sustain the habitual use of D2–40 staining
in the evaluation of risk categories.
In four of our cases (4.3%), the immunohistochemical
assessment of LVI would have changed the risk group of
the patients from low to intermediate. However, the rele-
vance of this upgrade for the management of the patient
cannot be assured. It has been evidenced elsewhere that
the presence of vascular invasion was significantly associ-
ated with poorer disease free survival both in the entire
Table 1: Correlation between evaluation of (lympho-)vascular invasion assessed by hematoxilin & eosin (H&E) staining and by 
immunohistochemistry using the D2–40 antibody
Vascular invasion assessed by H&E Lymph vascular invasion assessed by immunostaining with D2–40 Total
Negative Positive
Negative 64 22 86
Positive 1 5 6
Total 65 27 92
75% agreement; there was no relation between both methods by the Fisher's exact test (p = 0.335); accordingly, the difference between both 
methods of assessing vascular invasion was significantly different by the McNemar test (p < 0.0001)
Table 2: Correlation between (lympho-)vascular invasion and sentinel lymph node (SLN) status
SLN Vascular invasion assessed by H&E Lymph vascular invasion assessed by immunostaining with D2–40
Negative Positive Negative Positive
Negative 57 4 44 17
Positive 29 2 21 10
Total 86 6 65 27
p values* 0.090 0.376
* Fisher's exact testPage 4 of 8
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senting positive non-sentinel lymph node was consid-
ered. However, only the results obtained with D2–40, but
not on H&E stain, were statistically significant [29]. The
opposite has been stated in another study, in which the
authors referred a concordance of 78.2% between LVI in
H&E and with D2–40 (similar to ours, 75%). Only the
values obtained on H&E stained sections were correlated
with positive SLN [31]. In a recent report, when LVI was
correlated with the presence of micro and macrometas-
tases in axillary lymph nodes, only the evaluation on H&E
stains was significantly associated with the presence of
macrometastasis in SLN [17]. These differences raise the
issue that the increase in sensitivity in LVI detection by
immunohistochemistry might not be associated with clin-
ically relevant impact, meaning that only higher degrees
of vascular invasion easily detected on H&E stains are
important. The practical value of utilizing the presence of
LVI to predict SLN status could also be questioned, first
because SLN evaluation does not imply a major surgical
risk for the patient. In addition, most cases are diagnosed
in a small sample of the tumor, and the absence of LVI in
the original slides would not preclude SLN evaluation
[32]. Also, even in those studies which demonstrate corre-
lation between the presence of LVI and lymph node status
present a percentage of discordance, a fact that will make
it advisable to stick to the actual standardized procedures.
The significance shown herein between vascular invasion
assessed by H&E and risk categories is borderline and
might not correspond to a consistent biologic fact, as all
of the 13 cases placed in the high risk group showed neg-
ative SLN.
Another issue evidenced by the present findings is the
contradiction of the expected SLN colonization by tumor
cells, as they should be transported by the invaded peritu-
moral lymphatic vessels. A parallel verification could help
to explain this finding: neoplastic involvement of non-
SLN is not invariably present in patients with positive SLN
[33]. Then, it could be argued that the simple presence of
foci of neoplastic cells in more proximal regions of the
lymphatic flow does not necessarily imply in their capa-
bility of escaping defense mechanisms, which may pre-
vent their spread to the next step.
Assessment of vascular invasion in breast cancer is not
taken into account in a widely used prognostic index, but
it was included as a parameter in grouping patients with
different risks, using H&E stains [16,32]. Considering the
above data, it might be important to reevaluate the relia-
bility of including the assessment of LVI by immunohisto-
chemistry using the antibody D2–40 in the prognostic
index in large international trials, before using this
method individually, which could be hazardous for the
patient by overestimating the risk category. Such proce-
dure is technically viable and would allow the compari-
son of data from reports in which only conventionally
stained slides to detect vascular invasion have been used
Table 3: Correlation between four or more positive and negative + up to three sentinel lymph nodes (SLN) and status of (lympho-
)vascular invasion
SLN Vascular invasion assessed by H&E Lymph vascular invasion assessed by immunostaining with D2–40
Negative Positive Negative Positive
Negative or <4 positive 80 6 60 26
≥ 4 positive 6 0 5 1
Total 86 6 65 27
p values* 0.103 0.543
* Fisher's exact test
Table 4: Correlation between the three risk groups and status of (lympho-) vascular invasion
Risk groupsa Vascular invasion assessed by H&E Lymph vascular invasion assessed by immunostaining with D2–40
Negative Positive Negative Positive
Low 24 1 15 9
Intermediate 49 5 41 15
High 13 0 9 3
Total 86 6 65 27
p values* 0.040 0.221
* Fisher's exact test; a: according to Goldhirsh et al, 2005 [ref. # [16]]Page 5 of 8
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which LVI is searched should be considered the border of
neoplasia, as data on the lymphangiogenesis in inner
areas of the tumor and its possible relevance for prognosis
is a matter of debate, perhaps because of differences in the
markers used [24,31,37]. Quantification of vascular inva-
sion around the tumor should also be evaluated, as this
parameter could reflect more properly the likelihood of
dissemination of the disease, as suggested before [36]. In
other words, only pronounced vascular infiltration, rather
than focal or sparse, could more likely suggest that tumor
cells have acquired the potential to nest at distance.
For this purpose, D2–40 seems a good marker for lym-
phatic vessels, in spite of the possible pitfalls in interpre-
tation of its reactivity. Rabban & Chan (2008) suggested
that p63 should be simultaneously used to stain myoepi-
thelial cells when it renders difficult to distinguish
between lymphangiovascular invasion and stromal
myoepithelial cells in close relation to neoplastic cells
[38]. Arnaout-Alkarain et al (2007) have used anti-CD31
to assist decision taking in cases with discordant results
between LVI assessment with D2–40 and H&E [27]. It has
been also suggested that double staining using D2–40 in
conjunction with proliferation marker Ki-67 should be
preferred to avoid misinterpretation of LVI [39]. It should
be kept in mind that the opposite can occur. In cases of
minimal vascular invasion on H&E stains, further sections
obtained for immunohistochemistry may not represent
the same area of vascular invasion, resulting negative [17].
Our data demonstrated no association between MVD,
LVD, and VEGF-A protein expression with SLN status and
other clinicopathological features. Lack of relationship
between markers of angiogenesis and clinicopathological
features has been observed in other studies, but most
reports have shown prognostic value of increased MVD
and/or presence of LVI [12,24,28-31,40-44]. In additional
studies, however, multivariate analysis has eliminated the
prognostic value of angiogenic parameters [27,37]. The
reason for the discrepancy between our results and other
reports seems not to be related to selection bias, as we
have studied a well defined group of patients, using the
same clinical management protocol. We also used sensi-
tive markers and well established techniques to determine
MVD and LVD [45-47]. Moreover, the concordance rate
between the two observers was satisfactory. However,
unexpected drawbacks, such as inadequacy of antigen
preservation, or differences due to dissimilar sources of
antibodies might have accounted for this divergence.
The lack of correlation between LVD and SLN status also
seems in opposition to the reasonable concept that the
more vessels are around a tumor, the more likely it is to
metastasize. However, in this respect we are dealing with
the complex mechanisms of circulation and nesting of
neoplastic cells, which might not be properly evaluated by
the static methods used herein.
Conclusion
The data presented herein support the value of assessing
LVI by immunohistochemistry using D2–40, in increasing
the ratio of positive cases. It may be suggested that this
parameter should be included in the evaluation of risk
groups in patients with early breast cancer, in order to add
a more reproducible parameter to compare different trials,
and to determine in which extent this enhancement in
sensitivity of the method will reveal clinical relevance. For
now, the evidences from our study do not allow us to
advocate the use of LVI and MVD or LVD as predictors of
SLN invasion in breast cancer.
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